MA47420A - Composés inhibiteurs d'oga - Google Patents
Composés inhibiteurs d'ogaInfo
- Publication number
- MA47420A MA47420A MA047420A MA47420A MA47420A MA 47420 A MA47420 A MA 47420A MA 047420 A MA047420 A MA 047420A MA 47420 A MA47420 A MA 47420A MA 47420 A MA47420 A MA 47420A
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitor compounds
- oga inhibitor
- oga
- compounds
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17154751 | 2017-02-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47420A true MA47420A (fr) | 2019-12-11 |
Family
ID=57965815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047420A MA47420A (fr) | 2017-02-06 | 2018-02-06 | Composés inhibiteurs d'oga |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200048267A1 (fr) |
| EP (1) | EP3577121A1 (fr) |
| JP (1) | JP2020506940A (fr) |
| CN (1) | CN110267961A (fr) |
| AU (1) | AU2018216040A1 (fr) |
| CA (1) | CA3045816A1 (fr) |
| MA (1) | MA47420A (fr) |
| WO (1) | WO2018141984A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3868752A1 (fr) | 2014-08-28 | 2021-08-25 | Asceneuron SA | Inhibiteurs de la glycosidase |
| MA43677A (fr) | 2016-02-25 | 2018-11-28 | Asceneuron Sa | Inhibiteurs de glycosidases |
| EP3419972B1 (fr) | 2016-02-25 | 2023-07-26 | Asceneuron SA | Inhibiteurs de glycosidases |
| US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
| CN109071526B (zh) | 2016-02-25 | 2023-02-28 | 阿森纽荣股份公司 | 哌嗪衍生物的酸加成盐 |
| MA47591A (fr) * | 2017-02-27 | 2020-01-01 | Janssen Pharmaceutica Nv | Dérivés de [1,2,4]-triazolo [1,5-a]-pyrimidinyle substitués par de la pipéridine, de la morpholine ou de la pipérazine utilisés en tant qu'inhibiteurs d'oga |
| EP3672959A1 (fr) | 2017-08-24 | 2020-07-01 | Asceneuron SA | Inhibiteurs linéaires de la glycosidase |
| WO2020039028A1 (fr) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Inhibiteurs de tétrahydro-benzoazépine glycosidase |
| WO2020039027A1 (fr) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Inhibiteurs de pyrrolidine glycosidase |
| US11731972B2 (en) | 2018-08-22 | 2023-08-22 | Asceneuron Sa | Spiro compounds as glycosidase inhibitors |
| US20230060003A1 (en) * | 2019-10-29 | 2023-02-23 | Biogen Ma Inc. | Spirocyclic o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4749715B2 (ja) | 2002-07-05 | 2011-08-17 | ターガセプト，インコーポレイテッド | Ｎ−アリールジアザスピロ環式化合物、並びにその製造及び使用方法 |
| US20110071129A1 (en) | 2008-06-19 | 2011-03-24 | Makoto Ando | Spirodiamine-diaryl ketoxime derivative |
| TW201030007A (en) | 2009-02-06 | 2010-08-16 | Gruenenthal Gmbh | Substituted spiro-amides as b1r modulators |
| WO2010108268A1 (fr) * | 2009-03-23 | 2010-09-30 | Merck Frosst Canada Ltd. | Composés hétérocycliques inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase |
| WO2013066729A1 (fr) * | 2011-10-31 | 2013-05-10 | Merck Sharp & Dohme Corp. | Aminopyrimidinones en tant qu'inhibiteurs de kinases associées au récepteur de l'interleukine |
| PL2882733T3 (pl) * | 2012-08-08 | 2017-10-31 | Elanco Tiergesundheit Ag | Podstawione azyny jako pestycydy |
| CN105294655B (zh) * | 2014-07-26 | 2019-03-15 | 广东东阳光药业有限公司 | Cdk类小分子抑制剂的化合物及其用途 |
| EP3868752A1 (fr) * | 2014-08-28 | 2021-08-25 | Asceneuron SA | Inhibiteurs de la glycosidase |
| EP4074378A1 (fr) * | 2015-07-02 | 2022-10-19 | Janssen Sciences Ireland Unlimited Company | Composés antibactériens |
| US10323038B2 (en) * | 2015-11-20 | 2019-06-18 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| WO2017087858A1 (fr) * | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Composés de pyrazole, procédés de production et utilisation |
| US11186564B2 (en) * | 2016-08-04 | 2021-11-30 | Sunovion Pharmaceuticals Inc. | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders |
-
2018
- 2018-02-06 US US16/482,327 patent/US20200048267A1/en not_active Abandoned
- 2018-02-06 CA CA3045816A patent/CA3045816A1/fr not_active Abandoned
- 2018-02-06 CN CN201880010260.3A patent/CN110267961A/zh active Pending
- 2018-02-06 WO PCT/EP2018/052901 patent/WO2018141984A1/fr active Application Filing
- 2018-02-06 AU AU2018216040A patent/AU2018216040A1/en not_active Abandoned
- 2018-02-06 JP JP2019542375A patent/JP2020506940A/ja active Pending
- 2018-02-06 MA MA047420A patent/MA47420A/fr unknown
- 2018-02-06 EP EP18705346.7A patent/EP3577121A1/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018216040A1 (en) | 2019-06-20 |
| CA3045816A1 (fr) | 2018-08-09 |
| US20200048267A1 (en) | 2020-02-13 |
| CN110267961A (zh) | 2019-09-20 |
| WO2018141984A1 (fr) | 2018-08-09 |
| JP2020506940A (ja) | 2020-03-05 |
| EP3577121A1 (fr) | 2019-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47575A (fr) | Composés inhibiteurs d'oga monocyclique | |
| MA47576A (fr) | Composés inhibiteurs d'oga bicyclique | |
| MA52942A (fr) | Composés inhibiteurs d'oga | |
| MA52939A (fr) | Composés inhibiteurs d'oga | |
| MA47420A (fr) | Composés inhibiteurs d'oga | |
| DK3497103T3 (da) | Pyridopyrimdinon-cdk2/4/6-inhibitorer | |
| MA49701A (fr) | Composés immunomodulateurs | |
| MA44725A (fr) | Formulations d'un inhibiteur de lsd1 | |
| DK3601283T3 (da) | Kondenseret imidazo-piperidin-JAK-inhibitorforbindelse | |
| MA52948A (fr) | Composés | |
| MA51669A (fr) | Composés | |
| MA43169A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma | |
| MA46242A (fr) | Composés inhibiteurs de bêta-lactamase | |
| MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
| MA53003A (fr) | Composés | |
| DK3612519T3 (da) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl forbindelser | |
| MA46878A (fr) | Composés de benzodiazolium en tant qu'inhibiteurs d'enac | |
| MA49006A (fr) | Inhibiteurs d'ip6k | |
| MA41169A (fr) | Composés antibactériens à large spectre d'activité | |
| DK3630752T3 (da) | Substituerede nitrogenholdige forbindelser | |
| MA49621A (fr) | Composés bifonctionnels | |
| MA52946A (fr) | Composés | |
| MA51221A (fr) | Composés de pyrazolopyridinone | |
| DK3672941T3 (da) | Pyridylpyridonforbindelser | |
| MA52935A (fr) | Composés inhibiteurs d'oga |